Refex
REFEX is a combined antibacterial drug containing piperacillin, a semi-synthetic broad-spectrum antibiotic, and tazobactam, an inhibitor of most beta-lactamases. It has a wide range of action (Gr +, Gr-, anaerobes, protozoa), high clinical efficacy and low resistance in microorganisms.
Mechanism of action
Piperacillin – inhibits cell wall synthesis.
Tazobactam is an inhibitor of Richmoid Sykes’ beta-lactamase class IІІ: penicillinase and cephalosporinase.
The drug has bactericidal activity.
Indication:
- severe pneumonia, including nosocomial and ventilator-associated pneumonia;
- complicated intra-abdominal infections;
- complicated infections of the skin and soft tissues, urinary system;
- septicemia;
- bacterial infections in patients with neutropenia and fever with suspected bacterial infection
Dosage form:
Powder for solution for infusion.
1 vial of the drug (4500 mg) contains:
- piperacillin 4000 mg,
- tazobactam 500 mg.
Mode of application: intravenously.
Age restrictions: Do not apply to children under 2 years.
How supplied
4500 mg
Sales markets
Ukraine
Articles
- The piperacillin/tazobactam role in the treatment of complicated intra-abdominal infections (cIAI) in Ukrainian hospitals: 40 clinical cases series analysis
- Application of "Refex" at patients with purulent infections of pararectal areas
- Intraabdominal infection: peritonitis as abdominal sepsis. Principles of intensive therapy
- Antimicrobial therapy of severe “civilian” intra-abdominal infections: a modern approach to empiric antibiotic therapy
- Piperacillin/tazobactam in modern clinical practice